Xenon Pharmaceuticals Inc. (XENE) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 41 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | after close | 42 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026" exhibit |
| Q3 FY2026 | "Positive Phase 1 data for novel, non-opioid pain programs XEN1701 (Na V 1.7) and XEN1120 (K V 7) presented at IASP World Congress on Pain support initiating Phase 2 proof-of-concept studies in acute pain; studies expected to initiate in H1 2027" exhibit |
| Q3 FY2026 | "“Following the completion of enrollment in X-NOVA2, we are working toward our first Phase 3 data readout in psychiatry with topline results now expected in December 2026." exhibit |
| Q3 FY2026 | "The Company expects multiple new azetukalner and epilepsy data presentations at the American Epilepsy Society (AES) 2026 Annual Meeting, taking place December 4-8, 2026, in Denver, Colorado." exhibit |
| Q3 FY2026 | "The Phase 3 X-TOLE3 study of azetukalner in FS continues to enroll and is intended to support regulatory submissions outside of the U.S. X-TOLE3 enrollment outside of Japan is expected to complete in 2026." exhibit |
| Q2 FY2026 | "Three Phase 3 studies of azetukalner in neuropsychiatry continue to advance, with topline data from X-NOVA2 study in MDD expected H1 2027" exhibit |
| Q2 FY2026 | "Phase 1 studies of novel Na V 1.7 (XEN1701) and K V 7 (XEN1120) candidates expected to complete H2 2026; Phase 1 study underway for second Na V 1.7 (XEN1720) candidate for pain" exhibit |
| Q2 FY2026 | "“We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027." exhibit |
| Q2 FY2026 | "Xenon remains on track to submit its New Drug Application (NDA) for azetukalner in FOS in the third quarter of 2026, having completed a pre-NDA meeting with the U.S. Food and Drug Administration (FDA)." exhibit |
| Q2 FY2026 | "X-TOLE3 enrollment outside of Japan is expected to complete in 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/XENE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/XENE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/XENE/"><img src="https://veritasdata.dev/embed/XENE.svg" alt="XENE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/XENE/)
Script
<script async src="https://veritasdata.dev/embed/XENE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/XENE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.